Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Expansion into higher-margin specialty and oncology services successfully transforms the revenue mix.
Major Retail Network Loss: The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.
McKesson is an entrenched oligopoly player in pharmaceutical distribution. Its massive scale and steady cash flows fund an aggressive buyback program, offering a safe, compounding return profile.
McKesson is an entrenched oligopoly player in pharmaceutical distribution. Its massive scale and steady cash flows fund an aggressive buyback program, offering a safe, compounding return profile.
Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
High barriers to entry due to extreme capital and regulatory requirements.
Aging demographics and expanded specialty drug approvals drive sustained volume growth.
Strong Buy based on a wide margin of safety and highly visible capital returns.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACC normalizes to a higher tier, intrinsic value regressions toward the $737 downside boundary.
Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
High barriers to entry due to extreme capital and regulatory requirements.
Sticky customer relationships via integrated technology and services.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCF cliff sensitivity is not model-supported in this run; use the discount-rate and terminal-growth grid as the primary valuation pressure test.
If EPS exceeds internal valuation cross-checks, expect continued buyback acceleration. If margins compress, the stock will likely re-rate lower despite revenue growth.
If EPS exceeds internal valuation cross-checks, expect continued buyback acceleration. If margins compress, the stock will likely re-rate lower despite revenue growth.
Stable oligopoly allows for minimal capital reinvestment relative to operating cash flows, maximizing shareholder return.
Aging demographics and expanded specialty drug approvals drive sustained volume growth.
Generic deflation outpaces branded inflation, or regulatory changes shock pricing models.
Stable oligopoly allows for minimal capital reinvestment relative to operating cash flows, maximizing shareholder return.
Core holding for conservative, mature-compounder portfolios.
Re-evaluate if operating margins consistently fall below 1.0% or if the buyback program is suspended.
Strong Buy
The 40% upside combined with highly predictable, recession-resistant cash flows warrants a strong-Strong Buy rating despite low absolute margins.
MCK is rated Strong Buy at $725.17 versus the reconciled fair value midpoint of $1,016.12, implying +40.12% upside/downside.
At $725.17, the stock is measured against the final $1,016.12 midpoint and +40.12% upside/downside, so new capital should respect the report margin-of-safety discipline.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Heightened regulatory scrutiny on drug pricing and the potential loss of a major pharmacy network compress already thin margins. The WACC normalizes upward, compressing valuation toward the $737 floor.
The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.
Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.
Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.
The five developments that would weaken our investment case.
Drug wholesale distribution relies on razor-thin operating spreads and high inventory velocity. Regulatory drug pricing caps or commercial margin concessions that compress profitability below critical thresholds eliminate operating leverage, destroying wholesale economics and heavily reducing cash available for reinvestment or capital return.
Current:1.3% for the period ended 2025-03-31
Alert ifFalls below 1.0% over two consecutive quarters
Share repurchases and capital efficiency represent the primary vehicles for per-share compounding in a mature distribution oligopoly. Slower capital returns or resurgent litigation charges would impair capital allocation, lowering returns on capital and interrupting multi-year earnings per share growth.
Current:68.7% as of the 2026-05-13 analysis date
Alert ifFalls below 50.0% over any trailing twelve-month period
The wholesale model depends heavily on massive purchasing volume to secure tiered manufacturer rebates and negotiate supplier discounts. Losing a premier retail customer would cause sharp volume deleveraging, strand fixed distribution infrastructure, and contract overall operational profitability.
Current:3.7% for the period ended 2025-03-31
Alert ifCompresses below 3.0% over two consecutive quarters
Specialty distribution and oncology provider networks generate superior margins compared to commoditized retail prescription fulfillment. Decelerating revenue expansion suggests market share losses or slowing biopharma demand, dampening segment mix enrichment and capping consolidated earnings growth.
Current:16.2% for the period ended 2025-03-31
Alert ifDecelerates below 5.0% year-over-year over two consecutive quarters
Efficient working capital velocity is critical to converting low-margin distribution billings into dependable liquidity. Sustained decline in conversion ratios indicates receivable collection delays or inventory overhangs, reducing cash generation needed for debt obligations and ongoing capital returns.
Current:1.847 as of the 2026-05-13 analysis date
Alert ifFalls below 1.0x over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Expansion into higher-margin specialty and oncology services successfully transforms the revenue mix. Operating margins expand, and steady cash flows fuel aggressive buybacks, pushing value to the $1,308 high.
McKesson maintains its dominant oligopoly position. Predictable cash flows support steady share repurchases and dividends. Forward earnings trajectory bypasses WACC anomalies to deliver a $1,016 intrinsic value.
If EPS exceeds internal valuation cross-checks, expect continued buyback acceleration. If margins compress, the stock will likely re-rate lower despite revenue growth.
If EPS exceeds internal valuation cross-checks, expect continued buyback acceleration. If margins compress, the stock will likely re-rate lower despite revenue growth.
Warning level: Falls below 1.0% over two consecutive quarters. Drug wholesale distribution relies on razor-thin operating spreads and high inventory velocity. Regulatory drug pricing caps or commercial margin concessions that compress profitability below critical thresholds eliminate operating leverage, destroying wholesale economics and heavily reducing cash available for reinvestment or capital return.
Warning level: Falls below 50.0% over any trailing twelve-month period. Share repurchases and capital efficiency represent the primary vehicles for per-share compounding in a mature distribution oligopoly. Slower capital returns or resurgent litigation charges would impair capital allocation, lowering returns on capital and interrupting multi-year earnings per share growth.
Warning level: Compresses below 3.0% over two consecutive quarters. The wholesale model depends heavily on massive purchasing volume to secure tiered manufacturer rebates and negotiate supplier discounts. Losing a premier retail customer would cause sharp volume deleveraging, strand fixed distribution infrastructure, and contract overall operational profitability.
Warning level: Decelerates below 5.0% year-over-year over two consecutive quarters. Specialty distribution and oncology provider networks generate superior margins compared to commoditized retail prescription fulfillment. Decelerating revenue expansion suggests market share losses or slowing biopharma demand, dampening segment mix enrichment and capping consolidated earnings growth.
Warning level: Falls below 1.0x over any trailing twelve-month period. Efficient working capital velocity is critical to converting low-margin distribution billings into dependable liquidity. Sustained decline in conversion ratios indicates receivable collection delays or inventory overhangs, reducing cash generation needed for debt obligations and ongoing capital returns.
| $276.71B |
| $308.95B |
| $359.05B |
| +10.8% |
| Gross profit | $13.13B | $12.36B | $12.83B | $13.32B | +0.5% |
| Operating income | $2.11B | $4.88B | $4.04B | $4.62B | +30.0% |
| Net income | $1.11B | $3.56B | $3.00B | $3.30B | +43.5% |
| EPS (diluted) | $7.23 | $25.03 | $22.39 | $25.72 | +52.7% |
| EBITDA | $2.87B | $5.49B | $4.68B | $5.26B | +22.4% |
| R&D | — | — | — | — | — |
| SG&A | $10.54B | $7.78B | $8.66B | $8.51B | -6.9% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 359,051,000,000 |
|---|---|
| Cost of revenue | 345,728,000,000 |
| Gross profit | 13,323,000,000 |
| Operating expenses | 8,507,000,000 |
| Operating income | 4,816,000,000 |
| Non-operating items and tax | -1,521,000,000 |
| Net income | 3,295,000,000 |
| Total assets | 75,140,000,000 |
|---|---|
| Cash | 5,691,000,000 |
| Current assets | 55,398,000,000 |
| Total liabilities | 76,834,000,000 |
| Current liabilities | 61,604,000,000 |
| Shareholder deficit | 2,074,000,000 |
Point-in-time financial data used in the 2026-05-13 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-31 | 264B | 2.9B | 1.1B | 4.4B | 3.9B | 535M | 760M | — | 3.5B | 277M | — | — | — | — | — | 3.5B | 7.5B | 1.0% | — | 5.1% | — |
| 2023-03-31 | 276.7B | 5.5B | 3.6B | 5.2B | 4.6B | 558M | 608M | — | 3.6B | 292M | — | — | — | — | — | 4.7B | 7.3B | 1.7% | — | 5.7% | — |
| 2024-03-31 | 309B | 4.7B | 3B | 4.3B | 3.6B | 687M | 635M | — | 3B | 314M | — | — | — | — | — | 4.6B | 7.4B | 1.4% | — | 6.5% | — |
| 2025-03-31 | 359.1B | 5.3B | 3.3B | 6.1B | 5.2B | 859M | 636M | — | 3.1B | 345M | — | — | — | — | — | 5.7B | 7.4B | 1.3% | — | 5.7% | — |
MCK trades at 14.4x forward earnings against a peer median of 15.2x; EV/EBITDA of 13.5x against a peer median of 12.5x; 6 peers.
| Cardinal Health Inc. |
| 15.2x |
| 0.2x |
| 12.0x |
| — |
| 1.4% |
| HSIC | Henry Schein Inc. | 11.7x | 0.6x | 12.5x | 8.8% | 5.8% |
| LLY | Eli Lilly and Company | 22.4x | 12.2x | 25.4x | 107.5% | 49.4% |
| JNJ | Johnson & Johnson | 17.6x | 5.6x | 16.7x | 26.4% | 27.4% |
